MARKET

NSPR

NSPR

INSPIREMD
AMEX

Real-time Quotes | Nasdaq Last Sale

0.4292
+0.0002
+0.05%
After Hours: 0.4250 -0.0042 -0.98% 18:02 08/14 EDT
OPEN
0.4200
PREV CLOSE
0.4290
HIGH
0.4292
LOW
0.4166
VOLUME
660.80K
TURNOVER
--
52 WEEK HIGH
5.30
52 WEEK LOW
0.3860
MARKET CAP
14.32M
P/E (TTM)
-0.1752
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NSPR stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.

EPS

NSPR News

More
InspireMD regains compliance with NYSE listing rule
InspireMD (NYSEMKT:NSPR) has regained compliance with the NYSE American’s continued listing standards. Recently, the Company raised ~$10.7M from a funding
seekingalpha · 4d ago
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
Benzinga · 5d ago
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that as of Augus
GlobeNewswire · 5d ago
InspireMD shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.
Benzinga · 08/05 14:41
InspireMD shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.
Benzinga · 08/05 11:06
InspireMD Q2 EPS $(0.20) Beats $(0.35) Estimate, Sales $313.00K Beat $200.00K Estimate
InspireMD (AMEX:NSPR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.35) by 42.86 percent. This is a 87.42 percent increase over losses of $(1.59) per share from the same
Benzinga · 08/05 10:52
InspireMD Announces Second Quarter 2020 Financial Results
In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating patients with the CGuard™ MicroNET stent Management to host in
GlobeNewswire · 08/05 10:40
UPDATE: InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate Update
Conference Call to be held Wednesday, August 5, 2020 at 8:30am ETTEL AVIV, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by caro
GlobeNewswire · 07/29 20:05

Industry

Medical Equipment, Supplies & Distribution
-1.04%
Healthcare Equipment & Supplies
-1.20%

Hot Stocks

Symbol
Price
%Change

About NSPR

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
More

Webull offers kinds of InspireMD Inc stock information, including AMEX:NSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NSPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NSPR stock methods without spending real money on the virtual paper trading platform.